Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
BerGenBio ASA logo — Developing Innovative Drugs for Aggressive Diseases

BerGenBio ASA

Developing Innovative Drugs for Aggressive Diseases

Founded 2008 Norway Norway 23 employees Post Ipo Debt Total: $1.50B Biotechnology, Pharmaceutical

General Information

Company Name BerGenBio ASA
Founded Year 2008
Location Norway Norway +2
Employees 23
Industries Biotechnology, Pharmaceutical
Funding Stage Post Ipo Debt
Social

Get notified when BerGenBio ASA moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About BerGenBio ASA

BerGenBio ASA is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Norway. The company is dedicated to developing innovative drugs for aggressive diseases. BerGenBio is focused on creating a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. They are globally recognized for their understanding of the central role of AXL kinase in promoting cancer spread, immune evasion, and drug resistance, which accounts for approximately 90 percent of cancer deaths. The company's approach to inhibiting AXL kinase activity provides a novel strategy to address a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering new therapeutic options for cancer patients. Post-IPO Debt investment of kr250.00M in November 2023 demonstrates the confidence in BerGenBio's approach and potential in the biotechnology and pharmaceutical industries.

Taxonomy: biopharmaceutical, drug development, clinical-stage, cancer treatment, AXL kinase inhibitors, aggressive cancers, immune evasion, drug resistance, cancer research, therapeutic options, innovative drugs

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt •••••• - 30 Nov 2023
Post-IPO Debt •••••• 1 •••• •••• 25 Oct 2022
Post-IPO Equity •••••• - 05 May 2020
Post-IPO Equity •••••• - 30 Jan 2020
Post-IPO Equity •••••• - 13 Apr 2018

View All 10 Funding Rounds

BerGenBio ASA Alternatives & Competitors

BerGenBio ASA vs
AlloMek Therapeutics LLC
AlloMek Therapeutics LLC

Dedicated to advancing cancer treatment through innovative MEK kinase inhibitors.

Pre Seed
1 employees
Biotechnology, Health and Wellness
BerGenBio ASA vs
Advenchen Laboratories, LLC
Advenchen Laboratories, LLC

Pioneering novel therapies with promising small molecule kinase inhibitors for a brighter future in...

Series Unknown
6 employees
Biotechnology, Health Care
BerGenBio ASA vs
Phoenix Molecular Designs
Phoenix Molecular Designs United States

A clinical stage biopharmaceutical company designing precise cancer therapeutics to address unmet me...

Series A
22 employees
Biotechnology, Health Care

FAQ About BerGenBio ASA

Developing Innovative Drugs for Aggressive Diseases
BerGenBio ASA was founded in 2008.
BerGenBio ASA is headquartered in Norway.
BerGenBio ASA operates in the following industries: Biotechnology, Pharmaceutical.
BerGenBio ASA has approximately 23 employees.
BerGenBio ASA has completed 10 funding rounds, raising a total of $1.50B. The latest funding stage is Post Ipo Debt.
Top alternatives and competitors to BerGenBio ASA include AlloMek Therapeutics LLC, Advenchen Laboratories, LLC, Phoenix Molecular Designs, Ambit, Deciphera Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BerGenBio ASA and AlloMek Therapeutics LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors BerGenBio ASA and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy